Global donors reduce funding for HIV/AIDS treatment
The United States of America and other major donors to HIV/AIDs programmes in Africa have reduced its funding for anti-retroviral drugs and research.
The priorities to funding innovation in global healthcare has hit an all-time low in the annual investment for HIV prevention, research and development as major donors have reduced their support.
A new report released at the 9th International AIDS Society (IAS) Conference on HIV Science in Paris showed a continuous decline in funding and its potential impact on HIV patients and death rates.
The Resource Tracking for HIV Prevention, Research and Development Working Group’s, RTWG 13th Annual Report noted that funding for HIV prevention and research decreased by another three per cent in 2016.
According to the report, funding for HIV prevention R&D fell by three per cent ($35 million) in 2016 from the previous year, falling to $1.17 billion.
“It had maintained a steady downward trend between 2012 and 2016, falling from US$1.31 billion to US$1.17 billion with an annual funding loss of US$40.5 million, US$10.3 million, US$10.4 million and US$2.8 million for the four years.
The report which had tracked global funding for HIV science since 2000 also revealed that the United States’ public sector and the Bill & Melinda Gates Foundation donate about 88 cents of every dollar spent on HIV prevention R&D in 2016.
It added that the European public sector funding fell by $10 million from 2015 and at $59 million, accounted for just six per cent of all public sector investment, according to the 2016 research document.